Acer disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. For more information, visit www.acertx.com. Suggested guidelines for the diagnosis and management of urea cycle disorders. Acer’s pipeline includes four programs: ACER-001 (sodium phenylbutyrate) for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD); EDSIVO™ (celiprolol) for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation; ACER-801 (osanetant) for the treatment of induced Vasomotor Symptoms (iVMS); and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19. Currency in CHF. Mail; Finance Home. GENEVA, SWITZERLAND / ACCESSWIRE / October 8, 2020 / RELIEF THERAPEUTICS Holding AG (SIX:RLF)(OTCQB:RLFTF) ("Relief" or the "Company"), a biopharmaceutical company with its lead compound RLF-100TM (aviptadil) in advanced clinical development to treat severe COVID-19 patients, today announced the appointment of Jack Weinstein as Chief Financial Officer (CFO) and Treasurer, … Urea cycle disorders overview. Relief Therapeutics Holding AG, a biopharmaceutical company, provides patients with therapeutic relief in serious diseases with high unmet medical need. Find the latest RELIEF THERAPEUTICS N (RLF.SW) stock discussion in Yahoo Finance's forum. Relief also holds a US patent 1 for Aviptadil and proprietary manufacturing processes for its synthesis. Read full article . Anticipation of progress has driven shares in the Geneva-based company sharply higher this year. Relief Therapeutics stock fell more than 20% after the Swiss company on Wednesday said the U.S. Food and Drug Administration rejected its bid for emergency approval of the drug aviptdadil in critically ill COVID-19 patients. Reasons referenced for non-compliance associated with some available medications include unpleasant taste, the frequency with which medication must be taken, the number of pills, and the high cost of the medication.2 About Maple Syrup Urine Disease Maple Syrup Urine Disease (MSUD) is a rare but serious inherited condition whereby the human body cannot process certain amino acids, causing a harmful build-up of substances in the blood and urine. RELIEF THERAPEUTICS Holding AG (SIX:RLF), „Relief", hat den Beginn der klinischen FDA-Studien von Aviptadil an der Miller School of Medicine der University of Miami zur Behandlung des durch COVID-19 ausgelösten, akuten Atemnotsyndroms (ARDS) bekannt gegeben. No matching results for '' Tip: Try a valid symbol or a specific company name for relevant results. Under the terms of the Option Agreement, Acer will receive from Relief a $1 million non-refundable payment in return for exclusivity until June 30, 2021 to negotiate and enter into a definitive collaboration and license agreement between Acer and Relief for the development of ACER-001. Currency Converter; Canada markets open in 8 hours 17 minutes. RELIEF THERAPEUTICS Holding SA (SIX-RLF, "Relief" ou la "Société") annonce aujourd'hui que le Prof. Jonathan C. Javitt, DM, MPH sera proposé à l'élection du vice-président de son conseil d'administration lors de l'assemblée générale annuelle qui se tiendra le 19 juin 2012;7(32).Shchelochkov OA, et al. Biden Wants to Shut Down Credit Bureaus – What Would That Mean for You? RLF-100 is a synthetic form of human … About Acer Therapeutics Inc. Acer is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs. You should review additional disclosures Acer makes in its filings with the Securities and Exchange Commission, including its Quarterly Reports on Form 10-Q and its Annual Report on Form 10-K. You may access these documents for no charge at http://www.sec.gov. RELIEF THERAPEUTICS Holding SA (SIX-RLF, "Relief" ou la "Société") lance un essai clinique urgent de phase 2 du RLF-100 (Aviptadil) en coordination avec les hauts responsables du gouvernement israélien pour le traitement du syndrome de détresse respiratoire aiguë (SDRA) chez les patients atteints d'une infection au COVID-19. Acer to receive $1 million payment to obtain … The formulation is designed to be both taste-masked and immediate release. Orphanet Journal of Rare Diseases. Relief Therapeutics Holding AG reports 1H results seekingalpha.com - September 15 at 7:57 AM: Relief Reports Half-Year 2020 Results finance.yahoo.com - September 15 at 7:57 AM: Relief Therapeutics Holdings AG: Relief Appoints Gilles Della Corte, M.D. ACER-001’s stage of maturity fits perfectly within our strategic plan.” Chris Schelling, Acer’s CEO and Founder, said, “I believe Relief shares the same values and vision that Acer has in supporting the rare disease community. In addition, Relief will agree to pay up to $20 million in U.S. development and commercial launch costs for the UCDs and MSUD indications. Relief Therapeutics moves RLF-100 into compassionate use testing for ARDS due to COVID-19 in coordination with the Government of Israel About ACER-001 ACER-001 is a powder formulation of sodium phenylbutyrate (NaPB). Currently, Relief is concentrating its efforts on developing new treatments for respiratory disease indications. Relief Forward Looking Statements This communication expressly or implicitly contains certain forward-looking statements concerning RELIEF THERAPEUTICS Holding AG, Inc. and its businesses. Relief Therapeutics and Acer Therapeutics Sign Option Agreement for Exclusivity to Negotiate a Collaboration and License Agreement for the Worldwide Development and Commercialization of ACER-001 for the Treatment of Urea Cycle Disorders and Maple Syrup Urine Disease. The loan, which will be secured by a lien on all of Acer's assets, will bear interest at the rate of 6% per annum and will be due in one year. This potential collaboration could provide important resources and additional expertise to help bring ACER-001 to patients worldwide suffering from debilitating diseases like UCDs and MSUD. There can be no assurance, however, that a definitive agreement will be successfully negotiated and executed between the parties on these terms, on other mutually acceptable terms, or at all. All rights reserved. Acute hyperammonemia can cause lethargy, somnolence, coma, and multi-organ failure, while chronic hyperammonemia can lead to headaches, confusion, lethargy, failure to thrive, behavioral changes, and learning and cognitive deficits. Barriers to drug adherence in the treatment of urea cycle disorders: Assessment of patient, caregiver and provider perspectives. RELIEF THERAPEUTICS Holding AG is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbol RLFTF. 2016;8:43-47. Common symptoms of both acute and chronic hyperammonemia also include seizures and psychiatric symptoms.1,2 The current treatment of UCDs consists of dietary management to limit ammonia production in conjunction with medications that provide alternative pathways for the removal of ammonia from the bloodstream. as Chief Medical Officer finanznachrichten.de - September 4 at 4:45 AM NeuroRx and Relief Therapeutics Announce Data Monitoring Committee Determination to Continue Phase 2/3 Trial of RLF-100 for Critical COVID-19. RELIEF THERAPEUTICS Holding AG (SIX:RLF) "Relief" announces that its drug Aviptadil has now entered FDA clinical trials at the University of Miami Miller School of Medicine for the treatment of Acute Respiratory Distress Syndrome (ARDS) in COVID-19. Gene Reviews. GEM is Relief's longest standing shareholder, dating back to their initial investment in 2015, and currently owns over 1.3 billion shares of Relief common stock. Its lead drug candidate RLF-100TM (aviptadil) is being investigated in two placebo-controlled U.S. phase 2b/3 clinical trials in respiratory deficiency due to COVID-19. Further, Acer will retain development and commercialization rights in the U.S., Canada, Brazil, Turkey and Japan. There is no guarantee that this product candidate will receive FDA approval or become commercially available for the uses being investigated. For more information, visit www.relieftherapeutics.com. Share your opinion and gain insight from other stock traders and investors. The results reported herein may or may not be indicative of the results of future and larger clinical trials for ACER-001 for the treatment of UCDs and MSUD, nor whether the ongoing clinical trials of Relief's lead compound, RLF-100™ (aviptadil) in advanced clinical development to treat severe COVID-19 patients, will be successful. Further, in connection with entering into the Option Agreement, Relief will make a $4.0 million loan to Acer. © 2021 Verizon Media. The companies will split net profits from Acer’s territories 60:40 in favor of Relief. Acer may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, risks and uncertainties associated with Acer’s ability to successfully negotiate and execute a definitive collaboration agreement with Relief on the proposed terms, on other mutually acceptable terms, or at all, Acer’s ability to repay the $4 million secured loan from Relief, the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient resources to fund Acer’s various product candidate development programs and to meet its business objectives and operational requirements, the fact that the results of earlier studies and trials may not be predictive of future clinical trial results, the protection and market exclusivity provided by Acer’s intellectual property, risks related to the drug discovery and the regulatory approval process and the impact of competitive products and technological changes. Switzerland's Relief Therapeutics and U.S. partner NeuroRx said on Wednesday they struck deals with Bachem and Nephron Pharmaceuticals to supply and make a 50-year-old drug, aviptadil, that is in clinical trials against COVID-19. Under the terms of the proposed collaboration and license agreement, the key terms of which are set forth in the Option Agreement, if a definitive agreement is executed pursuant to these terms and closed by June 30, 2021, Acer will receive $15 million in cash (net $10 million, inclusive of the $1 million payment and offset by a repayment of the $4 million loan from Relief). ACER-001 (sodium phenylbutyrate) powder is a taste-masked, immediate release proprietary formulation in development for the treatment of urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD). ACER-001 (sodium phenylbutyrate) powder is a taste-masked, immediate release proprietary formulation in development for the treatment of urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD). Acer Forward-Looking Statements This press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. About RELIEF THERAPEUTICS Holding AG Relief focuses primarily on clinical-stage programs based on molecules of natural origin (peptides and proteins) with a history of clinical testing and use in human patients or a strong scientific rationale. Currency in USD, Your $1,400 stimulus checks coming 'within a week' of approval: Rep. Jim Clyburn, Super Bowl halftime show 2021: What to expect amid new COVID-19 protocols. Relief will also license the rights for the rest of the world, where Acer will receive from Relief a 15% net sales royalty on all revenues received in Relief’s territories. © 2021 Verizon Media. Jack Weinstein, Relief’s CFO and Treasurer said, “We are excited about the opportunity to work with the Acer team to potentially develop and commercialize ACER-001 worldwide. Acer could also receive a total of $6 million in milestones based on the first European (EU) marketing approvals for UCDs and MSUD. Subscribe to Premium to view Fair Value for RLF.SW, Acer to receive $1 million payment to obtain exclusivity and a $4 million loan from Relief Companies working toward negotiation and execution of a definitive collaborationand license agreement by June 30, 2021 GENEVA and NEWTON, Mass., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Relief Therapeutics Holding AG (SIX: RLF, OTCQB: RLFTF)(“Relief”), a biopharmaceutical company with its lead compound RLF-100TM (aviptadil) in advanced clinical development to treat severe COVID-19 patients, and Acer Therapeutics Inc. (Nasdaq: ACER)(“Acer”), a pharmaceutical company focused on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced that the companies have signed an Option Agreement providing exclusivity for the right to negotiate a potential collaboration and license agreement for worldwide development and commercialization for ACER-001. ACER-001 is under clinical investigation and its safety and efficacy have not been established. Relief holds a patent issued in the United States and various other countries covering potential formulations of RLF-100TM. The Data Monitoring Committee gave a positive opinion to continue the study of RLF-100 in patients with critical COVID-19 with respiratory failure. All rights reserved. Each of Acer’s product candidates is believed to present a comparatively de-risked profile, having one or more of a favorable safety profile, clinical proof-of-concept data, mechanistic differentiation and/or accelerated paths for development through specific programs and procedures established by the FDA. Some patients may also require individual branched-chain amino acid supplementation. Find the latest RELIEF THERAPEUTICS HOLDING AG (RLFTF) stock discussions in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors. Relief Therapeutics News & Analysen: Hier finden Sie die News & Analysen-Seite für den Wert Relief Therapeutics NeuroRx, Inc., in partnership with RELIEF THERAPEUTICS Holding AG (SIX:RLF) "Relief" today announced that the U.S. Food and Drug Administration (FDA) awarded Fast Track designation to NeuroRx for the investigation of RLF-100 (Aviptadil) for the treatment of acute lung injury/acute respiratory distress syndrome associated with COVID-19. The company focuses on clinical-stage programs based on molecules of natural origin (peptides and proteins) with a history of clinical use and either initial human activity with efficacy data or a strong scientific rationale. The human body breaks down protein foods such as meat and fish into amino acids. ACER-001 microparticles consist of a core center, a layer of active drug, and a taste-masking coating that quickly dissolves in the stomach, allowing taste to be neutralized while still allowing for rapid systemic release. Share your opinion and gain insight from other stock traders and investors. Share your opinion and gain insight from other stock traders and investors. CORPORATE CONTACTS RELIEF THERAPEUTICS Holding AG: Jack Weinstein Chief Financial Officer and Treasurer contact@relieftherapeutics.com ACER Therapeutics:Jim DeNike Acer Therapeutics Inc. +1 844-902-6100 jdenike@acertx.com MEDIA CONTACTS Relief (Europe): Anne Hennecke / Brittney Sojeva MC Services AG relief@mc-services.eu +49 (0) 211-529-252-14 INVESTOR RELATIONS CONTACTS Relief (Europe): Anne Hennecke / Brittney Sojeva MC Services AG relief@mc-services.eu +49 (0) 211-529-252-14 Acer Therapeutics:Hans Vitzthum LifeSci Advisors +1 617-430-7578 hans@lifesciadvisors.com. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of RELIEF THERAPEUTICS Holding AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Seattle, Washington: University of Washington, Seattle; 1993.Häberle J, et al. While our core focus remains squarely on the rapid advancement of RLF-100™ for treatment of respiratory conditions, primarily acute respiratory distress syndrome (ARDS) due to COVID-19 infection, we are committed to establishing a diversified marketed product portfolio. Share your opinion and gain insight from other stock traders and investors. Relief Forward Looking Statements This communication expressly or implicitly contains certain forward-looking statements concerning RELIEF THERAPEUTICS Holding AG, Inc. and its businesses. Discover new investment ideas by accessing unbiased, in-depth investment research, Other OTC - Other OTC Delayed Price. References Ah Mew N, et al. News; Video; Watchlists; My Portfolio; My Screeners ; Tech; Market Data. If ACER-001 is approved, its taste-masked properties could make it a compelling alternative to existing NaPB-based treatments, as the unpleasant taste associated with NaPB is cited as a major impediment to patient compliance with those treatments.3 Acer has been granted orphan drug designation by the FDA for the MSUD indication. Other than a highly-restricted diet of branched-chain amino acid (BCCA) free synthetic foods and formula, there are no currently approved treatments for MSUD. RELIEF THERAPEUTICS Holding AG est cotée à la Bourse suisse SIX sous le symbole RLF. January 24, 2021, 10:30 PM. Find the latest RELIEF THERAPEUTICS N (RLF.SW) stock discussions in Yahoo Finance's forum. Discover new investment ideas by accessing unbiased, in-depth investment research, Swiss - Swiss Delayed Price. Relief Therapeutics said its partner NeuroRx and the Quantum Leap Healthcare Collaborative signed an agreement to include Zyesami in the I-SPY COVID-19 clinical trial, a platform trial assessing multiple drugs for critically ill COVID-19 patients. Relief Therapeutics says aviptadil, a synthetic vasoactive intestinal polypeptide, is the first COVID-19 therapeutic to block replication of the SARS-CoV-2 virus in human lung cells. Except for the $1.0 million upfront payment to Acer and the $4.0 million one-year secured loan from Relief to Acer, the remaining proposed terms of the collaboration are not binding and are subject to change as a result of further diligence by Relief and negotiation of a definitive collaboration and license agreement between the parties. RELIEF THERAPEUTICS Holding AG is providing this communication as of this date and do not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. Get RELIEF THERAPEUTICS Holding SA (RLFTF:OTCQB) real-time stock quotes, news, price and financial information from CNBC. Recherchez les dernières actualités, les cotations boursières et l’historique RELIEF THERAPEUTICS HOLDING SA (0QKQ.L), ainsi que d’autres informations essentielles qui vous aideront dans vos transactions et investissements. Correction: NeuroRx and Relief announce initial successful results from expanded access use of RLF-100™ (aviptadil) in patients with Critical COVID-19 and Severe Comorbidity: 72% survival seen in ICU patients . Share your opinion and gain insight from other stock traders and investors. Relief also holds a patent issued in the United States and various other countries covering potential formulations of RLF-100TM.RELIEF THERAPEUTICS Holding AG is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbol RLFTF.Follow us on LinkedIn CONTACT RELIEF THERAPEUTICS Holding AG Raghuram (Ram) Selvaraju, Ph.D., MBA Chairman of … 07 December 2020. ACER-001 is being developed using a microencapsulation process for the treatment of various inborn errors of metabolism, including UCDs and MSUD. Relief Therapeutics Aktie: Hier finden Sie den Relief Therapeutics Aktienkurs aktuell und ausserdem weitere Informationen wie den Relief Therapeutics Chart According to a 2016 study by Shchelochkov et al., published in Molecular Genetics and Metabolism Reports, while nitrogen scavenging medications can be effective in helping to manage ammonia levels in some patients with UCDs, non-compliance with treatment is common. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, timelines, future financial position, future revenues, projected expenses, regulatory submissions, actions or approvals, cash position, liquidity, prospects, plans and objectives of management are forward-looking statements. Such statements are based on management’s current expectations and involve risks and uncertainties. We very much look forward to the possibility of working with the Relief team.” About Urea Cycle Disorders (UCDs) Urea Cycle Disorders (UCDs) are a group of disorders caused by genetic mutations that result in a deficiency in one of the six enzymes that catalyze the urea cycle, which can lead to an excess accumulation of ammonia in the bloodstream, a condition known as hyperammonemia. Find the latest RELIEF THERAPEUTICS HOLDING AG (RLFTF) stock discussion in Yahoo Finance's forum. Relief Therapeutics Holding AG, a biopharmaceutical company, provides patients with therapeutic relief in serious diseases with high unmet medical need. This partnership is Relief’s first initiative to build a pipeline of drugs beyond RLF-100™. (Nasdaq: ACER)("Acer"), a pharmaceutical company focused on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced that the companies have signed an Option Agreement providing exclusivity for the right to negotiate a potential collaboration and license agreement for worldwide development and commercialization for ACER-001. Find the latest RELIEF THERAPEUTICS N (RLF.SW) stock discussions in Yahoo Finance's forum. Relief Therapeutics holds FDA and EU orphan drug designations for the use of VIP to treat ARDS, pulmonary hypertension, and sarcoidosis. Find the latest RELIEF THERAPEUTICS HOLDING AG (RLFTF) stock discussions in Yahoo Finance's forum. Industry News. Current medical treatments for UCDs include nitrogen scavengers RAVICTI® and BUPHENYL® in which the active pharmaceutical ingredients are glycerol phenylbutyrate (GPB) and sodium phenylbutyrate (NaPB), respectively. Mol Genet Metab. Relief Therapeutics and NeuroRx Meet 165 Patient Enrollment Target in Phase 2b/3 Trial of RLF-100™ for Critical COVID-19 with Respiratory Failure . Search. Información en tiempo real sobre las acciones de Relief Therapeutics Holding SA (RLFTF) en bolsa, incluyendo precio, gráficos, análisis técnico, datos históricos y mucho más. Examples of such statements include, but are not limited to, statements relating to the structure, terms, timing and entry into a definitive agreement for the proposed collaboration between Acer and Relief with respect to ACER-001; the shared values, vision and results of the potential collaboration of Acer and Relief; the potential for ACER-001 to target diseases; the adequacy of Acer’s capital to support its future operations and its ability to successfully continue its development programs; Acer’s ability to secure the additional capital necessary to fund its various product candidate development programs; and the development and commercial potential of any of Acer’s product candidates including ACER-001. Yahoo. https://www.sec.gov/Archives/edgar/data/1719406/000119312521019278/d56937ds4.htm, https://patientdaily.com/stories/573477964-promising-drug-helps-florida-man-with-covid-19. Find the latest RELIEF THERAPEUTICS N (RLF.SW) stock quote, history, news and other vital information to help you with your stock trading and investing.